Wall Street brokerages expect Trupanion Inc (NASDAQ:TRUP) to report ($0.04) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for Trupanion’s earnings. The lowest EPS estimate is ($0.06) and the highest is ($0.01). Trupanion reported earnings of ($0.05) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 20%. The firm is scheduled to announce its next earnings results on Tuesday, May 1st.
According to Zacks, analysts expect that Trupanion will report full year earnings of ($0.05) per share for the current year, with EPS estimates ranging from ($0.09) to $0.01. For the next year, analysts anticipate that the firm will report earnings of $0.11 per share, with EPS estimates ranging from $0.02 to $0.19. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Trupanion.
Trupanion (NASDAQ:TRUP) last posted its quarterly earnings results on Tuesday, February 13th. The financial services provider reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.03). The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $65.60 million. Trupanion had a negative return on equity of 6.66% and a negative net margin of 0.62%.
Trupanion (TRUP) traded up $0.27 during midday trading on Monday, hitting $36.07. 188,396 shares of the company’s stock were exchanged, compared to its average volume of 342,009. The stock has a market capitalization of $1,078.59, a PE ratio of -603.23 and a beta of 0.57. Trupanion has a fifty-two week low of $13.88 and a fifty-two week high of $36.88. The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 0.19.
In other news, Director Murray B. Low sold 3,000 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $28.42, for a total value of $85,260.00. Following the sale, the director now owns 194,281 shares in the company, valued at $5,521,466.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Darryl Rawlings sold 3,500 shares of the stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $30.11, for a total transaction of $105,385.00. Following the completion of the sale, the insider now owns 1,389,976 shares in the company, valued at approximately $41,852,177.36. The disclosure for this sale can be found here. Insiders sold 20,500 shares of company stock worth $635,005 in the last quarter. Company insiders own 31.24% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. First Mercantile Trust Co. acquired a new stake in shares of Trupanion in the fourth quarter worth $129,000. JPMorgan Chase & Co. acquired a new stake in Trupanion during the third quarter valued at $143,000. Advisor Group Inc. acquired a new stake in Trupanion during the fourth quarter valued at $182,000. Voya Investment Management LLC acquired a new stake in Trupanion during the second quarter valued at $215,000. Finally, Oppenheimer Asset Management Inc. acquired a new stake in Trupanion during the third quarter valued at $221,000. Hedge funds and other institutional investors own 74.75% of the company’s stock.
Trupanion Company Profile
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.